Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.
Alexandre Naime BarbosaAntonio SilvinatoHelio Arthur BachaIdevaldo FlorianoSuzana Erico TanniWanderley Marques BernardoPublished in: Revista da Associacao Medica Brasileira (1992) (2022)